TY - JOUR
T1 - The risk of acute myocardial infarction with etodolac is not increased compared to naproxen
T2 - A historical cohort analysis of a generic COX-2 selective inhibitor
AU - Warner, John J.
AU - Weideman, Rick A.
AU - Kelly, Kevin C.
AU - Brilakis, Emmanouil S.
AU - Banerjee, Subhash
AU - Cunningham, Francesca
AU - Harford, William V.
AU - Kazi, Salahuddin
AU - Little, Bertis B.
AU - Cryer, Byron
PY - 2008/12
Y1 - 2008/12
N2 - Background: This study compares the risk of acute myocardial infarction among patients exposed to etodolac, naproxen, celecoxib, and rofecoxib. Methods: A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib. Results: Diagnosis of acute myocardial infarction was confirmed in 100 patients who were exposed to a study nonsteroidal anti-inflammatory drug. Compared to naproxen, the increased risk of acute myocardial infarction was not significant for etodolac (OR = 1.32, P =.27), whereas celecoxib (OR = 2.18, 95% CI 1.09-4.35, P =.03) and rofecoxib (OR = 2.16, 95 CI 1.04-4.46, P =.04) were significant. A post hoc analysis indicates that patients with a prior history of acute myocardial infarction had a significant, 4.26-fold risk for another acute myocardial infarction if taking celecoxib or rofecoxib. Conclusion: Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen.
AB - Background: This study compares the risk of acute myocardial infarction among patients exposed to etodolac, naproxen, celecoxib, and rofecoxib. Methods: A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib. Results: Diagnosis of acute myocardial infarction was confirmed in 100 patients who were exposed to a study nonsteroidal anti-inflammatory drug. Compared to naproxen, the increased risk of acute myocardial infarction was not significant for etodolac (OR = 1.32, P =.27), whereas celecoxib (OR = 2.18, 95% CI 1.09-4.35, P =.03) and rofecoxib (OR = 2.16, 95 CI 1.04-4.46, P =.04) were significant. A post hoc analysis indicates that patients with a prior history of acute myocardial infarction had a significant, 4.26-fold risk for another acute myocardial infarction if taking celecoxib or rofecoxib. Conclusion: Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen.
KW - AMI
KW - COX-2
KW - Celecoxib
KW - Cohort
KW - Epidemiology
KW - Etodolac
KW - Naproxen
KW - Rofecoxib
UR - http://www.scopus.com/inward/record.url?scp=57649217921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57649217921&partnerID=8YFLogxK
U2 - 10.1177/1074248408323136
DO - 10.1177/1074248408323136
M3 - Article
C2 - 18787084
AN - SCOPUS:57649217921
SN - 1074-2484
VL - 13
SP - 252
EP - 260
JO - Journal of Cardiovascular Pharmacology and Therapeutics
JF - Journal of Cardiovascular Pharmacology and Therapeutics
IS - 4
ER -